The enigmatic role of IL-38 in inflammatory diseases. (February 2018)

• Record Type: Journal Article
• Authors: Garraud, Thomas; Harel, Mathilde; Boutet, Marie-Astrid; Le Goff, Benoit; Blanchard, Frédéric
• Is Part Of: Cytokine & growth factor reviews. Volume 39(2018)
• Page Start: 26
• Page End: 35
• Publication Date: 2018-02
• Subjects: IL-1F interleukin 1 family -- RA rheumatoid arthritis -- AS ankylosing spondylitis -- PsA psoriatic arthritis -- CRP C-reactive protein -- TH T Helper -- PBMCs peripheral blood mononuclear cells -- SLE systemic lupus erythematous -- IL-1RacP IL-1 receptor accessory protein -- NFκB nuclear factor kappa B -- MAPK mitogen associated protein kinases -- DAMPS danger associated molecular patterns -- PAMPS pathogen associated molecular patterns -- MMP matrix metallo peptidase -- NLS nuclear localization signal -- rh recombinant human -- TIR toll interleukin receptor -- TLR toll-like receptor -- JNK/AP1 Janus kinase/accessory protein 1 -- LPS lipopolysaccharide -- NLRP3 NOD-like receptor family, pyrin domain containing 3 -- STIA serum transfer induced arthritis -- CIA collagen induced arthritis -- AIA antigen induced arthritis -- DIRA deficit in IL-1 receptor antagonist -- DITRA deficit in IL-36 receptor antagonist; IL-38 -- IL-1F -- Inflammation -- Arthritis; Cytokines -- Periodicals; 571.84
• DOI: 10.1016/j.cytogfr.2018.01.001
• Languages: English
• ISSNs: 1359-6101

Abstract

Highlights: IL-38 is an anti inflammatory cytokine from the IL-1F. IL-38 maturation is still poorly understood but is mandatory to exert its biological activity. The receptor for IL-38 is still a matter of debate as it is able to bind 3 different receptor chains. IL-38 might exert its role especially by decreasing the secretion of TH-17 cytokines by macrophages. It is therefore an interesting cytokine to study in TH17 dependent diseases such as psoriatic arthritis. Abstract: IL-38 is the most recently discovered cytokine of the IL-1 family and is considered a potential inhibitor of the IL-1 and Toll-like receptor families. IL-38 exerts anti-inflammatory properties, especially on macrophages, by inhibiting secretion of pro-inflammatory cytokines, leading to reduced T-lymphocyte TH17 maturation. IL-38 has been studied most extensively in the context of chronic inflammatory diseases, particularly arthritis, where it is considered an attractive new drug candidate. IL-38 research has entered a new phase, with the realization that IL-38 is important in the pathophysiology of TH17 dependent-diseases (psoriasis, psoriatic arthritis and ankylosing spondylitis). In this review, we provide a critical evaluation of several controversial issues concerning IL-38 function and regulation. There is effectively contrasting data regarding IL-38: it is produced in conditions such as apoptosis, necrosis or inflammation, but data is lacking regarding IL-38 processing and biological function. Furthermore, the receptor for IL-38 has yet to be identified, although three candidate receptors – IL-1R1, IL-36R and IL-1RAPL1–have been proposed. Future studies will hopefully uncover new aspects of this enigmatic cytokine.